The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) last traded at $120.42, down -0.07% from the previous session.
JAZZ stock price is now -1.63% away from the 50-day moving average and -5.08% away from the 200-day moving average. The market capitalization of the company currently stands at $7.51B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $160, Robert W. Baird recently initiated with Outperform rating for Jazz Pharmaceuticals plc (NASDAQ: JAZZ). On November 27, 2023, UBS Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $170 to quote $135, while ‘Raymond James’ rates the stock as ‘Mkt Perform’
In other news, Carr Patricia, SVP, Chief Accounting Officer sold 1,768 shares of the company’s stock on Mar 07 ’24. The stock was sold for $206,821 at an average price of $116.98. Upon completion of the transaction, the SVP, Chief Accounting Officer now directly owns 6,596 shares in the company, valued at $0.79 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 06 ’24, SVP, Chief Accounting Officer Carr Patricia sold 1,936 shares of the business’s stock. A total of $231,628 was realized by selling the stock at an average price of $119.64. This leaves the insider owning 8,364 shares of the company worth $1.01 million. A total of 3.31% of the company’s stock is owned by insiders.
During the past 12 months, Jazz Pharmaceuticals plc has had a low of $111.25 and a high of $147.98. As of last week, the company has a debt-to-equity ratio of 1.55, a current ratio of 2.12, and a quick ratio of 1.74. According to the stock market information, the enterprise value for the company is $11.68B, which is based on a 20.86 price-to-earnings ratio, a 5.35 price-to-earnings-growth ratio, and a beta of 0.59. The fifty day moving average price for JAZZ is $122.41 and a two-hundred day moving average price translates $126.86 for the stock.
The latest earnings results from Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at $5.02, missing analysts’ expectations of $5.18 by -0.16. This compares to -$3.84 EPS in the same period last year. The net profit margin was 10.82% and return on equity was 12.16% for JAZZ. The company reported revenue of $1.01 billion for the quarter, compared to $972.12 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 4.1 percent. For the current quarter, analysts expect JAZZ to generate $956.6M in revenue.
